JP4782342B2 - フェノキシプロパノールアミン類、それらの製造方法およびそれらを含む医薬組成物 - Google Patents

フェノキシプロパノールアミン類、それらの製造方法およびそれらを含む医薬組成物 Download PDF

Info

Publication number
JP4782342B2
JP4782342B2 JP2001544882A JP2001544882A JP4782342B2 JP 4782342 B2 JP4782342 B2 JP 4782342B2 JP 2001544882 A JP2001544882 A JP 2001544882A JP 2001544882 A JP2001544882 A JP 2001544882A JP 4782342 B2 JP4782342 B2 JP 4782342B2
Authority
JP
Japan
Prior art keywords
alkyl
phenoxy
propanol
hydroxy
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001544882A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003517013A5 (https=
JP2003517013A (ja
Inventor
セッチ，ロベルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9915932A external-priority patent/FR2802529B1/fr
Priority claimed from FR9915931A external-priority patent/FR2802531B1/fr
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of JP2003517013A publication Critical patent/JP2003517013A/ja
Publication of JP2003517013A5 publication Critical patent/JP2003517013A5/ja
Application granted granted Critical
Publication of JP4782342B2 publication Critical patent/JP4782342B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2001544882A 1999-12-17 2000-12-14 フェノキシプロパノールアミン類、それらの製造方法およびそれらを含む医薬組成物 Expired - Fee Related JP4782342B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR9915932A FR2802529B1 (fr) 1999-12-17 1999-12-17 Phenoxypropanolamines, procede pour les preparer et compositions pharmaceutiques les contenant
FR9915931A FR2802531B1 (fr) 1999-12-17 1999-12-17 Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
FR99/15932 1999-12-17
FR99/15931 1999-12-17
PCT/FR2000/003535 WO2001043744A1 (fr) 1999-12-17 2000-12-14 Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant

Publications (3)

Publication Number Publication Date
JP2003517013A JP2003517013A (ja) 2003-05-20
JP2003517013A5 JP2003517013A5 (https=) 2008-02-14
JP4782342B2 true JP4782342B2 (ja) 2011-09-28

Family

ID=26235183

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001544882A Expired - Fee Related JP4782342B2 (ja) 1999-12-17 2000-12-14 フェノキシプロパノールアミン類、それらの製造方法およびそれらを含む医薬組成物

Country Status (7)

Country Link
US (1) US6867220B2 (https=)
EP (1) EP1242083B1 (https=)
JP (1) JP4782342B2 (https=)
AT (1) ATE356624T1 (https=)
AU (1) AU2525801A (https=)
DE (1) DE60033964T2 (https=)
WO (1) WO2001043744A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
CO5300399A1 (es) 2000-02-25 2003-07-31 Astrazeneca Ab Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
US7074934B2 (en) * 2000-06-13 2006-07-11 Tularik Limited Serine protease inhibitors
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
US7005439B2 (en) 2000-06-20 2006-02-28 Astrazeneca Ab Compounds
US6498170B2 (en) 2000-07-17 2002-12-24 Wyeth Cyclamine sulfonamides as β-3 adrenergic receptor agonists
US6410734B1 (en) 2000-07-17 2002-06-25 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6506901B2 (en) 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US6444685B1 (en) 2000-07-17 2002-09-03 Wyeth N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
AR035230A1 (es) 2001-03-19 2004-05-05 Astrazeneca Ab Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
SE0101038D0 (sv) 2001-03-23 2001-03-23 Astrazeneca Ab Novel compounds
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
SE0301369D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
EP1947103A1 (en) * 2007-01-22 2008-07-23 4Sc Ag Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments
MA44037B1 (fr) * 2016-06-06 2020-03-31 Arena Pharm Inc Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci
LT3483164T (lt) 2017-03-20 2020-05-11 Forma Therapeutics, Inc. Pirolpirolo kompozicijos kaip piruvato kinazės (pkr) aktyvatoriai
CN111699189B (zh) * 2017-12-06 2025-02-18 艾尼纳制药公司 可用于治疗或预防与其相关的心力衰竭和障碍的β-3肾上腺素能受体的调节剂
EP3852791B1 (en) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activating pyruvate kinase r
EP3853206B1 (en) 2018-09-19 2024-04-10 Novo Nordisk Health Care AG Treating sickle cell disease with a pyruvate kinase r activating compound
HRP20251148T1 (hr) 2019-09-19 2025-11-21 Novo Nordisk Health Care Ag Pripravci koji aktiviraju piruvat-kinazu r (pkr)
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58206581A (ja) * 1982-05-13 1983-12-01 ゲロト−フアルマツオイチカ・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング ピロガロ−ルの新規な環置換誘導体
WO1999052872A1 (en) * 1998-04-09 1999-10-21 Meiji Seika Kaisha, Ltd. AMINOPIPERIDINE DERIVATIVES AS INTEGRIN αvβ3 ANTAGONISTS
JP2004504299A (ja) * 2000-07-17 2004-02-12 ワイス 環状アミンフェニルベータ−３アドレナリン作用性受容体アゴニスト

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3524955A1 (de) 1984-07-19 1986-01-30 Sandoz-Patent-GmbH, 7850 Lörrach 3-aminopropoxyaryl-derivate, ihre herstellung und sie enthaltende arzneimittel
GB2163150B (en) * 1984-07-19 1988-05-25 Sandoz Ltd 3-aminopropoxyaryl derivatives
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
PE92198A1 (es) * 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
FR2780057B1 (fr) * 1998-06-18 2002-09-13 Sanofi Sa Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
US6444685B1 (en) * 2000-07-17 2002-09-03 Wyeth N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58206581A (ja) * 1982-05-13 1983-12-01 ゲロト−フアルマツオイチカ・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング ピロガロ−ルの新規な環置換誘導体
WO1999052872A1 (en) * 1998-04-09 1999-10-21 Meiji Seika Kaisha, Ltd. AMINOPIPERIDINE DERIVATIVES AS INTEGRIN αvβ3 ANTAGONISTS
JP2004504299A (ja) * 2000-07-17 2004-02-12 ワイス 環状アミンフェニルベータ−３アドレナリン作用性受容体アゴニスト

Also Published As

Publication number Publication date
EP1242083A1 (fr) 2002-09-25
US20030040530A1 (en) 2003-02-27
DE60033964T2 (de) 2007-11-29
US6867220B2 (en) 2005-03-15
ATE356624T1 (de) 2007-04-15
JP2003517013A (ja) 2003-05-20
WO2001043744A1 (fr) 2001-06-21
AU2525801A (en) 2001-06-25
DE60033964D1 (de) 2007-04-26
EP1242083B1 (fr) 2007-03-14

Similar Documents

Publication Publication Date Title
JP4782342B2 (ja) フェノキシプロパノールアミン類、それらの製造方法およびそれらを含む医薬組成物
DK3075726T3 (en) URE ADDITIVES OR PHARMACOLOGICAL ACCEPTABLE SALTS THEREOF USE AS FORMYLPEPTIDE RECEPTOR LIKE 1- (FPRL-1) AGONISTS
CA2332538C (en) Novel 4-phenylpiperidines for the treatment of pruritic dermatoses
JP2003528046A (ja) フェノキシプロパノールアミン類、それらの製造および治療的使用
WO2000074681A1 (en) Metalloprotease inhibitors
WO2004013100A2 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
CZ362599A3 (cs) Indazolamidové sloučeniny jako serotoninergní přípravky
CN102164920A (zh) 烷基噻唑氨基甲酸酯衍生物、其制备方法和其作为faah酶抑制剂的用途
DE60316683T2 (de) Phenylcyclohexylpropanolaminderivate, deren herstellung und therapeutsche anwendung
US7718646B2 (en) Cyclohexyl(alkyl)propanolamines, preparation method and pharmaceutical compositions containing same
TW401417B (en) 4-Aryloxy- and 4-arylthiopiperidine derivatives
JP4704643B2 (ja) ヘテロアリールオキシプロパノールアミン、その製造方法及びそれらを含有する医薬組成物
JP4746253B2 (ja) プロパノールアミノテトラリン類、その製造及びそれらを含む組成物
JP4499034B2 (ja) Ｎ−アリール又はｎ−ヘテロアリールピペラジン誘導体及びそれを含有する医薬
JP2008515887A (ja) アリールチオベンジルピペリジン誘導体
JP2005535599A (ja) オキソフェニルシクロヘキシルプロパノールアミン誘導体、それらの製造法、およびそれらの治療的適用
US20060079523A1 (en) Arylthiobenzylpiperidine derivatives
JP2002145860A (ja) 生活習慣病用医薬
FR2802529A1 (fr) Phenoxypropanolamines, procede pour les preparer et compositions pharmaceutiques les contenant

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110425

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110506

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110525

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110621

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110707

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140715

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees